GENFERON LIGHT 50 000 IU COMBINED INTERFERON BASED IMMUNOMODULATOR (spray)

GENFERON LIGHT 50 000 IU SPRAY COMBINED INTERFERON BASED IMMUNOMODULATOR is designed for the prevention and treatment of influenza and acute respiratory viral infections in adults and adolescents over 14 years of age.

Ingredients:

COMPOSITION PER NASAL SPRAY DOSE

Each dose of the preparation contains the following active ingredients: recombinant human interferon alpha-2b - 50,000 IU, taurine - 1.0 mg.

Inactive ingredients: disodium edetate dihydrate 0.02 mg, glycerol 7.0 mg, dextran 40000 2.4 mg, polysorbate 80 1.0 mg, sodium chloride 0.8 mg, potassium chloride 0.02 mg, sodium hydrogen phosphate dodecahydrate 0.115 mg, potassium dihydrogen phosphate 0.02 mg, peppermint oil 0.01 mg, methyl parahydroxybenzoate 0.02 mg, purified water in a sufficient amount.

Pharmacological action:

GENFERON® LIGHT contains recombinant human interferon alpha-2b produced using genetically engineered Escherichia coli bacteria carrying the human interferon alpha-2b gene. Interferon alpha-2b demonstrates antiviral, immunomodulating, antibacterial, and antiproliferative properties.

The antiviral activity is associated with stimulation of intracellular enzymes that suppress viral replication. The immunomodulating effect is mainly expressed through enhancement of cell-mediated immune responses, increasing the body’s resistance to viruses, intracellular pathogens, and tumor-altered cells. This is achieved by activation of CD8+ cytotoxic T-cells and NK (natural killer) cells, stimulation of B-lymphocyte differentiation and antibody synthesis, activation of phagocytosis and the monocyte-macrophage system, as well as increased expression of major histocompatibility complex class I molecules, improving immune recognition of infected cells.

Interferon also stimulates leukocyte activity within the mucosal layers, supporting elimination of infection sites, and restores production of secretory immunoglobulin A. The antibacterial effect is associated with immune reactions enhanced by interferon activity.

Taurine contributes to normalization of metabolic processes and tissue regeneration while providing membrane-protective and immunomodulating effects.

As a potent antioxidant, taurine interacts directly with reactive oxygen species, preventing their excessive accumulation associated with pathological conditions. Taurine also helps preserve the biological activity of interferon, enhancing the therapeutic effectiveness of the preparation.

Directions for use and dosage:

The preparation is administered intranasally using aerosol delivery of a single dose (1 dose = one short press of the dispenser).

At the first symptoms of illness, GENFERON® LIGHT spray is used intranasally for 5 days: one dose (one press) into each nostril 3 times daily. One dose contains approximately 50,000 IU of interferon alpha; the total daily dose should not exceed 500,000 IU.

After contact with a person with acute respiratory viral infection and/or after hypothermia, the preparation should be administered according to the indicated regimen twice daily for 5–7 days. Preventive courses may be repeated if required.
Instructions for use:

1. Remove the protective cap.
2. Before the first application, press the dispenser several times until a fine spray appears.
3. Keep the bottle in an upright position during use.
4. Spray the preparation into each nostril with one press of the dispenser.
5. Replace the protective cap after use.

To reduce the risk of infection transmission, individual use of the bottle is recommended.

Effect:

Intranasal administration provides a pronounced local antiviral and immune-supporting effect due to the high concentration of active substances at the site of infection. Systemic absorption is minimal because the nasal mucosa contains specialized proteins regulating the transport of molecular and cellular substances across the mucosal barrier.

At the same time, a small amount of the preparation enters systemic circulation, contributing to an additional systemic immunomodulating effect.

Contraindications:

Hypersensitivity to interferon or any component of the preparation.

Special instructions:

INTERACTION WITH OTHER MEDICATIONS
Simultaneous use with intranasal vasoconstrictor agents is not recommended, as they may additionally dry the nasal mucosa.

EFFECT ON THE ABILITY TO DRIVE VEHICLES AND OPERATE MACHINERY
GENFERON® LIGHT spray does not affect the ability to perform activities requiring increased concentration and rapid psychomotor reactions, including driving and operating machinery.

Packaging and release form:

Metered-dose nasal spray 50,000 IU/dose + 1 mg/dose. The preparation is supplied in dark neutral hydrolytic class I glass bottles containing 100 doses, sealed with a spray dispenser and protective cap. Each bottle is labeled and packed together with instructions for use in a cardboard carton.

Storage conditions:

Store and transport in a dry, protected-from-light place at a temperature between 2°C and 8°C.
Keep out of reach of children.

Guaranteed authenticity and quality:

100% Original from BIOCAD (Russian Federation)

BIOCAD is one of Russia’s leading biotechnology companies, delivering a complete cycle of preparation research, development, and manufacturing for the treatment of cancer, autoimmune, and genetic diseases.

BIOCAD manages the full pharmaceutical development process: from molecular discovery and genetic engineering to large-scale production.

OTC PHARM - stable leader in the over-the-counter preparation market.

OTC PHARM strive to improve people's quality of life by setting high standards for the domestic pharmaceutical industry.

Development and production:

BIOCAD or OTC PHARM